News
科思
/
/
/
Stent Thrombosis With Drug-Eluting Stents and Bioresorbable Scaffolds: Evidence From a Network Meta-Analysis of 147 Trials.

Stent Thrombosis With Drug-Eluting Stents and Bioresorbable Scaffolds: Evidence From a Network Meta-Analysis of 147 Trials.

  • Categories:Academic Paper
  • Author:
  • Origin:
  • Time of issue:2015-08-04 08:55
  • Views:

(Summary description)This study sought to perform a systematic review and network meta-analysis to compare the relative safety and efficacy of contemporary DES and BVS.

Stent Thrombosis With Drug-Eluting Stents and Bioresorbable Scaffolds: Evidence From a Network Meta-Analysis of 147 Trials.

(Summary description)This study sought to perform a systematic review and network meta-analysis to compare the relative safety and efficacy of contemporary DES and BVS.

  • Categories:Academic Paper
  • Author:
  • Origin:
  • Time of issue:2015-08-04 08:55
  • Views:
Information

  OBJECTIVES: This study sought to perform a systematic review and network meta-analysis to compare the relative safety and efficacy of contemporary DES and BVS.

  BACKGROUND: To improve outcomes of patients undergoing percutaneous coronary revascularization, there have been advances in the design of drug-eluting stents (DES), including the development of drug-eluting bioresorbable vascular scaffolds (BVS).

  METHODS: Prospective, randomized, controlled trials comparing bare-metal stents (BMS), paclitaxel-eluting stents (PES), sirolimus-elutingstents (SES), Endeavor zotarolimus-eluting stents (E-ZES), cobalt-chromium (CoCr) everolimus-eluting stents (EES), platinum-chromium (PtCr)-EES, biodegradable polymer (BP)-EES, Resolute zotarolimus-eluting stents (R-ZES), BP biolimus-eluting stents (BP-BES), hybrid sirolimus-eluting stents (H [Orsiro]-SES), polymer-free sirolimus- and probucol-eluting stents, or BVS were searched in online databases. The primary endpoint was definite or probable stent thrombosis at 1 year.

  RESULTS: A total of 147 trials including 126,526 patients were analyzed in this study. All contemporary DES were superior to BMS and PES in terms of definite or probable stent thrombosis at 1 year. CoCr-EES, PtCr-EES, and H-SES were associated with significantly lower risk than BVS. CoCr-EES and H-SES were superior to SES and BP-BES. The risk of myocardial infarction was significantly lower with H-SES than with BVS. There were no significant differences regarding all-cause or cardiac mortality. Contemporary devices including BVS showed comparably low risks of repeat revascularization.

  CONCLUSIONS: Contemporary DES, including biocompatible DP-DES, BP-DES, and polymer-free DES, showed a low risk of definite or probablestent thrombosis at 1 year. BVS had an increased risk of device thrombosis compared with CoCr-EES, PtCr-EES, and H-SES. Data from extended follow-up are warranted to confirm the long-term safety of contemporary coronary devices.

PeriSorb® fully degradable peripheral vascular stent completes the first FIM trial enrollment
2021 12-25

PeriSorb® fully degradable peripheral vascular stent completes the first FIM trial enrollment

This is the world's first 3D printed fully degradable peripheral stent implanted in the human body, marking that my country's 3D printing fully degradable peripheral stent with completely independent intellectual property rights has taken the lead in entering the clinical trial stage, and it also marks that my country's 3D printing technology has advanced to the world's leading level. A big step.
Beijing adds 1,150 municipal-level "specialized, special and new" small and medium-sized enterprises
2021 12-03

Beijing adds 1,150 municipal-level "specialized, special and new" small and medium-sized enterprises

On December 1, the Beijing Economic and Information Bureau announced the list of the second to seventh batch of "specialized, special and new" small and medium-sized enterprises in Beijing in 2021. The list includes 1,150 small and medium-sized enterprises including Labtech, Digital Video, Geling Shentong, Moji Fengyun Technology, etc.
Beijing Amet was recognized as a "specialized, special and new" enterprise
2021 12-02

Beijing Amet was recognized as a "specialized, special and new" enterprise

On December 1, 2021, the Beijing Municipal Bureau of Economy and Information issued an announcement on the seventh batch of "specialized, refined, and new" small and medium-sized enterprises in 2021. The announcement announced that Beijing Amet Medical Equipment Co., Ltd. was recognized as a "specialized, refined and new" enterprise. This event marks that Amet, as an innovative enterprise, has reached a high level in terms of scientific research strength, technical level and influence, and has been recognized by the competent government departments.

Company Information

Beijing Advanced Medical Technologies,Ltd.Inc.

Contact Us

Address: Building 11, Zhongguancun Medical Equipment Park, No. 26, Yongwang West Road, Daxing District, Beijing

Tel:010-6297-7955           E-Mail:amt@ametcorp.com